Endoscopic Endonasal Transsphenoidal Surgery for Recurrent Craniopharyngiomas

Zhenguang Feng, Chuzhong Li, Lei Cao, Ning Qiao, Wentao Wu, Jiwei Bai, Peng Zhao, Songbai GuiFrontiers in Neurology 2022 · DOI

TL;DR

Revision surgery for recurrent craniopharyngiomas is notoriously difficult due to scar tissue and high complication risks. This study demonstrates that Endoscopic Endonasal Transsphenoidal Surgery (EETS) is a safe and effective alternative to traditional open-head surgery, achieving total tumor removal in over 55% of cases with significant visual improvements and minimal serious complications.

What Problem Does This Paper Address?

Craniopharyngiomas are benign but aggressive brain tumors located in the "high-rent district" of the skull base—near the pituitary gland, optic nerves, and hypothalamus. While the initial surgery is challenging, recurrent tumors are a neurosurgical nightmare.

Previous surgeries leave behind dense scar tissue (gliotic reactions) and destroy natural anatomical landmarks, making it incredibly difficult to separate the tumor from vital structures like the internal carotid artery. Traditional "open" revision surgeries (transcranial) carry high rates of morbidity and mortality. The authors sought to evaluate whether the endoscopic endonasal approach—entering through the nose with a camera—could provide a safer, more effective route for these complex repeat cases.

Methods

The researchers conducted a retrospective analysis of 28 patients (representing 29 surgical cases) treated between 2014 and 2018.

The Surgical Approach: * Group 1 (Previous Craniotomy): For patients who previously had "open" surgery, the nasal corridor was a "virgin route," meaning surgeons didn't have to fight through old scar tissue to reach the tumor. * Group 2 (Previous EETS): For those who had previous nasal surgery, the team used advanced tools like image guidance and intraoperative Doppler to locate the internal carotid arteries through existing scars. * Resection Strategy: They utilized "sharp separation" to gently peel the tumor away from neurovascular structures, prioritizing safety over "aggressive" removal if the tumor was too tightly adherent to the brain.

Datasets

As a clinical study, the "dataset" consists of the institutional patient cohort:

  • Cohort: 28 patients (22 men, 7 women).
  • Surgical History: 16 patients had one prior surgery, 10 had two, and 3 had three or more.
  • Follow-up: Patients were tracked for an average of 781 days (ranging from ~9 months to nearly 5 years).

Key Insights and Ideas

  • The "Virgin Route" Advantage: One of the most important takeaways is that for patients who failed a traditional craniotomy, EETS offers a fresh surgical corridor. This avoids the "minefield" of previous surgical scars in the brain tissue.
  • Vision Over Hormones: The study highlights a clear trade-off. While EETS is excellent for decompressing the optic nerves and improving sight, it is rarely able to restore endocrine (hormonal) function. In fact, the surgery often results in new hormonal deficits, such as Diabetes Insipidus (DI).
  • Adhesion is the Limiting Factor: The primary reason for incomplete tumor removal (Subtotal Resection) wasn't the surgical approach itself, but rather the tumor’s physical "stickiness" to the hypothalamus or carotid artery. The authors argue that leaving a tiny "tolerable" remnant is better than causing a stroke or permanent hypothalamic damage.
  • Safety Profile: Despite the complexity of revision surgery, the study reported zero deaths and very few major complications (only one CSF leak and one cured case of meningitis), suggesting EETS is remarkably robust.

Key Results

  • Extent of Resection:
    • Gross Total Resection (GTR): 55.17% (16/29)
    • Subtotal Resection (STR): 37.93% (11/29)
    • Partial Resection (PR): 6.9% (2/29)
  • Visual Outcomes: Of the 22 patients with preoperative vision loss, 81.8% (18/22) saw improvement. Only one patient experienced a deterioration in vision.
  • Endocrine Outcomes: No patients saw an improvement in hormonal function. Six patients developed new-onset Diabetes Insipidus post-surgery.
  • Morbidity: No serious long-term morbidity or mortality occurred across the entire cohort.

Limitations and Future Work

The authors acknowledge several constraints:

  • Sample Size: 28 patients is a relatively small cohort, though typical for specialized skull base studies.
  • Follow-up Duration: Craniopharyngiomas can recur many years later. The average follow-up of ~2 years is insufficient to declare these patients "cured."
  • Selection Bias: This was a retrospective study at a high-volume center; results might differ in less specialized settings.

Future Work: The team suggests that long-term, multi-center studies are needed to compare EETS directly against repeat craniotomies and to better define which tumor characteristics (like calcification or specific locations) most benefit from the endonasal route.

Summary updated

Abstract

For recurrent craniopharyngiomas, a personalized treatment plan should be developed according to the tumor characteristics and the patient's situation. There is no omnipotent method to be used for all patients. The EETS still is a safe and effective way to treat recurrent craniopharyngiomas in appropriate patients.
BibTeX
@inproceedings{feng2022endoscopic,
  author = {Zhenguang Feng and Chuzhong Li and Lei Cao and Ning Qiao and Wentao Wu and Jiwei Bai and Peng Zhao and Songbai Gui},
  title = {{Endoscopic Endonasal Transsphenoidal Surgery for Recurrent Craniopharyngiomas}},
  booktitle = {Frontiers in Neurology},
  year = {2022},
  doi = {10.3389/fneur.2022.847418},
}
Figure